Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 405 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Constipation Clear all
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01309841
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 21, 2026, 5:36 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting No phase listed Observational

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

NCT03720613
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Lubiprostone, Naloxegol
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
34,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

NCT06553547
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 11 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Not listed No phase listed Observational

Colonic Transit Time Validation Study

NCT00857363
View directory record Official record
Conditions
Constipation
Interventions
Not listed
Lead sponsor
The SmartPill Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

NCT01533155
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Nektar 118, Quinidine, Quinidine placebo, Morphine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Bacillus Subtilis DE111® on Daily Bowel Movements

NCT04083521
View directory record Official record
Conditions
Bowel Movement Regulation, Occasional Constipation, Occasional Diarrhea
Interventions
Bacillus subtilis DE111®
Dietary Supplement
Lead sponsor
Deerland Enzymes
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adherence/Outcomes After Use of Constipation Action Plan

NCT03821532
View directory record Official record
Conditions
Constipation - Functional
Interventions
Constipation Action Plan
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
4 Years to 8 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

NCT05989763
View directory record Official record
Conditions
Systemic Sclerosis, Constipation, Gastrointestinal Motility Disorder, Autonomic Dysfunction
Interventions
Transcutaneous Electrical Acustimulation (TEA), Sham-TEA
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 21, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome Analysis of Constipated Versus Non-constipation Patients

NCT04106232
View directory record Official record
Conditions
Rome IV Functional Constipation
Interventions
No change in procedure except for specimen collection throughout procedure
Other
Lead sponsor
HyGIeaCare, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Flowood, Mississippi • Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Tenapanor in Synucleinopathy-Related Constipation

NCT06460038
View directory record Official record
Conditions
Synucleinopathy, Parkinson's Disease
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Cedar Valley Digestive Health Center
Other
Eligibility
50 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Waterloo, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

NCT02727751
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 21, 2026, 5:36 AM EDT
Completed No phase listed Observational

Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy

NCT01618292
View directory record Official record
Conditions
Pelvic Organ Prolapse, Constipation, Bowel Dysfunction, Irritable Bowel Syndrome
Interventions
Robotic sacral colpopexy
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
Female only
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"Anticipatory Guidance in the Nursery and Its Impact on Non-urgent Emergency Department Visits"

NCT01859065
View directory record Official record
Conditions
Health Knowledge, Attitudes, Practice, Sneezing, Constipation, Nasal Congestion and Inflammations
Interventions
Intensified anticipatory guidance, Routine
Behavioral
Lead sponsor
Bronx-Lebanon Hospital Center Health Care System
Other
Eligibility
Female only
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

NCT00672477
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
29
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 21, 2026, 5:36 AM EDT
Terminated Phase 3 Interventional

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT00607971
View directory record Official record
Conditions
Constipation-Predominant Irritable Bowel Syndrome
Interventions
Renzapride
Drug
Lead sponsor
Alizyme
Industry
Eligibility
18 Years and older · Female only
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
126
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2008 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

NCT01642914
View directory record Official record
Conditions
Chronic Constipation, Constipation
Interventions
Linaclotide 290 micrograms, Linaclotide 145 micrograms, Matching placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
146
States / cities
Chandler, Arizona • Glendale, Arizona • Goodyear, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 4 Interventional

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

NCT05995899
View directory record Official record
Conditions
IBS, IBS - Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Kyle Staller, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00399659
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2006 – 2007
U.S. locations
57
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

NCT01372423
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Anchen Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
79
States / cities
Dothan, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

SAT vs Escitalopram for Rectal Hypersensitivity

NCT00584571
View directory record Official record
Conditions
Rectal Hypersensitivity, Irritable Bowel Syndrome-Constipation
Interventions
Sensory Adaptation Training, Escitalopram Therapy
Procedure · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Augusta, Georgia • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 21, 2026, 5:36 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Assessment and Validation of Electronic Gas and Bloating Diary

NCT04684849
View directory record Official record
Conditions
Gas, Bloating, Distension, Constipation, Diarrhea
Interventions
APP Diary, Paper Diary
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 21, 2026, 5:36 AM EDT